5YYF
 
 | |
6IPY
 | |
6IPZ
 | | Fyn SH3 domain R96W mutant, crystallized with 18-crown-6 | | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, Tyrosine-protein kinase Fyn | | Authors: | Arold, S.T, Aljedani, S.S, Shahul Hameed, U.F. | | Deposit date: | 2018-11-05 | | Release date: | 2018-11-28 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (1.576 Å) | | Cite: | Synergy and allostery in ligand binding by HIV-1 Nef.
Biochem.J., 478, 2021
|
|
7MJU
 | |
6KN1
 | | P20/P12 of caspase-11 mutant C254A | | Descriptor: | Caspase-4 | | Authors: | Ding, J, Sun, Q. | | Deposit date: | 2019-08-02 | | Release date: | 2020-03-11 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis.
Cell, 180, 2020
|
|
6KN0
 | |
6KMZ
 | |
6KMU
 | | P22/P10 complex of caspase-11 mutant C254A | | Descriptor: | Caspase-4 | | Authors: | Ding, J, Sun, Q. | | Deposit date: | 2019-08-01 | | Release date: | 2020-03-11 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis.
Cell, 180, 2020
|
|
6KMT
 | | P32 of caspase-11 mutant C254A | | Descriptor: | Caspase-4 | | Authors: | Ding, J, Sun, Q. | | Deposit date: | 2019-08-01 | | Release date: | 2020-03-11 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis.
Cell, 180, 2020
|
|
6KMV
 | |
8X8O
 | | Cryo-EM structure of a bacteriophage tail- spike protein against Klebsiella pneumoniae K64,ORF41(K64-ORF41) in 5 mM EDTA | | Descriptor: | Probable tail spike protein | | Authors: | Xie, Y, Huang, T, Zhang, Z, Tao, X. | | Deposit date: | 2023-11-27 | | Release date: | 2024-09-04 | | Last modified: | 2025-06-25 | | Method: | ELECTRON MICROSCOPY (2.5 Å) | | Cite: | Structural and functional basis of bacteriophage K64-ORF41 depolymerase for capsular polysaccharide degradation of Klebsiella pneumoniae K64.
Int.J.Biol.Macromol., 265, 2024
|
|
8X8M
 | | Cryo-EM structure of a bacteriophage tail- spike protein against Klebsiella pneumoniae K64,ORF41(K64-ORF41) | | Descriptor: | Probable tail spike protein | | Authors: | Xie, Y, Huang, T, Zhang, Z, Tao, X. | | Deposit date: | 2023-11-27 | | Release date: | 2024-09-04 | | Last modified: | 2025-06-25 | | Method: | ELECTRON MICROSCOPY (2.37 Å) | | Cite: | Structural and functional basis of bacteriophage K64-ORF41 depolymerase for capsular polysaccharide degradation of Klebsiella pneumoniae K64.
Int.J.Biol.Macromol., 265, 2024
|
|
7BWJ
 | | crystal structure of SARS-CoV-2 antibody with RBD | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1, antibody heavy chain, ... | | Authors: | Wang, X, Ge, J. | | Deposit date: | 2020-04-14 | | Release date: | 2020-06-03 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.85 Å) | | Cite: | Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Nature, 584, 2020
|
|
7CHO
 | | Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1, antibody P5A-1D2 heavy chain, ... | | Authors: | Wang, X, Zhang, L, Ge, J, Wang, R, Zhang, Q. | | Deposit date: | 2020-07-06 | | Release date: | 2021-05-19 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.561 Å) | | Cite: | Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
Nat Commun, 12, 2021
|
|
7CHS
 | | Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1, antibody P22A-1D1 heavy chain, ... | | Authors: | Wang, X, Zhang, L, Ge, J, Wang, R, Zhang, Q. | | Deposit date: | 2020-07-06 | | Release date: | 2021-05-19 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (2.401 Å) | | Cite: | Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
Nat Commun, 12, 2021
|
|
7CHP
 | | Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1, antibody P5A-3C8 heavy chain, ... | | Authors: | Wang, X, Zhang, L, Ge, J, Wang, R, Zhang, Q. | | Deposit date: | 2020-07-06 | | Release date: | 2021-05-19 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (2.357 Å) | | Cite: | Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2.
Nat Commun, 12, 2021
|
|
8VLF
 | |
8VLD
 | |
8VLH
 | |
8VWX
 | | Human Bcl-2 (G101V Mutant)/Bcl-xL Chimera Fused to Maltose-Binding Protein | | Descriptor: | Maltose/maltodextrin-binding periplasmic protein fused to apoptosis regulator Bcl-2/Bcl-xL chimera | | Authors: | Baird, J, Holliday, M. | | Deposit date: | 2024-02-02 | | Release date: | 2024-10-02 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (1.77 Å) | | Cite: | Hydrogen/Deuterium Exchange and Protein Oxidative Footprinting with Mass Spectrometry Collectively Discriminate the Binding of Small-Molecule Therapeutics to Bcl-2.
Anal.Chem., 97, 2025
|
|
8VXN
 | | Human Bcl-2/Bcl-xL Chimera Fused to Maltose-Binding Protein | | Descriptor: | Maltose/maltodextrin-binding periplasmic protein fused to apoptosis regulator Bcl-2/Bcl-xL chimera | | Authors: | Baird, J, Holliday, M. | | Deposit date: | 2024-02-05 | | Release date: | 2024-10-02 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.09 Å) | | Cite: | Hydrogen/Deuterium Exchange and Protein Oxidative Footprinting with Mass Spectrometry Collectively Discriminate the Binding of Small-Molecule Therapeutics to Bcl-2.
Anal.Chem., 97, 2025
|
|
8VXM
 | | Human Bcl-2/Bcl-xL Chimera Fused to MBP in Complex with Inhibitor S55746 | | Descriptor: | DI(HYDROXYETHYL)ETHER, Maltose/maltodextrin-binding periplasmic protein fused to apoptosis regulator Bcl-2/Bcl-xL chimera, ~{N}-(4-hydroxyphenyl)-3-[6-[[(3~{S})-3-(morpholin-4-ylmethyl)-3,4-dihydro-1~{H}-isoquinolin-2-yl]carbonyl]-1,3-benzodioxol-5-yl]-~{N}-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide | | Authors: | Baird, J, Holliday, M. | | Deposit date: | 2024-02-05 | | Release date: | 2024-10-02 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | Hydrogen/Deuterium Exchange and Protein Oxidative Footprinting with Mass Spectrometry Collectively Discriminate the Binding of Small-Molecule Therapeutics to Bcl-2.
Anal.Chem., 97, 2025
|
|
8VWZ
 | | Human Bcl-2 (G101V Mutant)/Bcl-xL Chimera Fused to MBP in Complex with Inhibitor S55746 | | Descriptor: | DI(HYDROXYETHYL)ETHER, Maltose/maltodextrin-binding periplasmic protein fused to apoptosis regulator Bcl-2/Bcl-xL chimera, ~{N}-(4-hydroxyphenyl)-3-[6-[[(3~{S})-3-(morpholin-4-ylmethyl)-3,4-dihydro-1~{H}-isoquinolin-2-yl]carbonyl]-1,3-benzodioxol-5-yl]-~{N}-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide | | Authors: | Baird, J, Holliday, M. | | Deposit date: | 2024-02-02 | | Release date: | 2024-10-02 | | Last modified: | 2025-03-12 | | Method: | X-RAY DIFFRACTION (2.33 Å) | | Cite: | Hydrogen/Deuterium Exchange and Protein Oxidative Footprinting with Mass Spectrometry Collectively Discriminate the Binding of Small-Molecule Therapeutics to Bcl-2.
Anal.Chem., 97, 2025
|
|
7WRP
 | | Crystal Structure of pks13-ACP domain from Corynebacterium diphtheriae | | Descriptor: | 4'-PHOSPHOPANTETHEINE, Polyketide synthase involved in mycolic acid biosynthesis | | Authors: | Liu, X. | | Deposit date: | 2022-01-27 | | Release date: | 2022-02-23 | | Last modified: | 2023-11-29 | | Method: | X-RAY DIFFRACTION (1.794 Å) | | Cite: | Crystal structures of FadD32 and pks13-ACP domain from Corynebacterium diphtheriae.
Biochem.Biophys.Res.Commun., 590, 2022
|
|
7V7M
 | | crystal structure of SARS-CoV-2 3CL protease | | Descriptor: | 3C-like proteinase | | Authors: | Yi, Y, Zhang, M, Ye, M. | | Deposit date: | 2021-08-21 | | Release date: | 2022-06-29 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (2.08 Å) | | Cite: | Schaftoside inhibits 3CL pro and PL pro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19.
Acta Pharm Sin B, 12, 2022
|
|
